(Q42928480)

11 November 2017

title

Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer (English)

1 reference

11 November 2017

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer (English)

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

21 June 2024

main subject

phase III clinical trial

0 references

1 reference

1 reference

1 reference

Andreas du Bois

1

1 reference

11 November 2017

Jørn Herrstedt

2

1 reference

11 November 2017

Anne-Claire Hardy-Bessard

3

1 reference

11 November 2017

Hans-Helge Müller

4

1 reference

11 November 2017

Philipp Harter

5

1 reference

11 November 2017

Gunnar Kristensen

6

1 reference

11 November 2017

Florence Joly

7

1 reference

11 November 2017

Jens Huober

8

1 reference

11 November 2017

Elisabeth Avall-Lundqvist

9

1 reference

11 November 2017

Béatrice Weber

10

1 reference

11 November 2017

Christian Kurzeder

11

1 reference

11 November 2017

Svetislav Jelic

12

1 reference

11 November 2017

Eric Pujade-Lauraine

13

1 reference

11 November 2017

Alexander Burges

14

1 reference

11 November 2017

Jacobus Pfisterer

15

1 reference

11 November 2017

Martina Gropp

16

1 reference

11 November 2017

Anne Staehle

17

1 reference

11 November 2017

Pauline Wimberger

18

1 reference

11 November 2017

Christian Jackisch

19

1 reference

11 November 2017

Jalid Sehouli

20

1 reference

11 November 2017

language of work or name

English

0 references

publication date

23 August 2010

1 reference

full work available at URL

11 November 2017

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.27.4696

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733132

http://intl.jco.org/cgi/content/abstract/28/27/4162

21 June 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733132

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.27.4696

21 June 2024

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Journal of Clinical Oncology

21 June 2024

published in

1 reference

11 November 2017

volume

28

1 reference

11 November 2017

issue

27

1 reference

11 November 2017

page(s)

4162-4169

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 June 2024

2

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 June 2024

3

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 June 2024

4

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

21 June 2024

5

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 June 2024

6

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

21 June 2024

7

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

21 June 2024

8

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 June 2024

9

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer

21 June 2024

10

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning

21 June 2024

11

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

21 June 2024

12

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).

21 June 2024

13

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 June 2024

16

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Letter: Creatinine clearance: bedside estimate.

21 June 2024

17

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 June 2024

19

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer

21 June 2024

20

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2024

22

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

21 June 2024

23

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint

21 June 2024

24

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Interim analysis: the alpha spending function approach.

21 June 2024

25

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

A general statistical principle for changing a design any time during the course of a trial

21 June 2024

26

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Journal of Clinical Oncology

21 June 2024

27

23

448

Kristensen GB

2004

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 June 2024

28

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

21 June 2024

29

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 June 2024

32

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o

21 June 2024

33

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy

21 June 2024

34

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens

21 June 2024

35

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials

21 June 2024

36

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

21 June 2024

37

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 June 2024

38

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

21 June 2024

39

1 reference

https://api.crossref.org/works/10.1200/JCO.2009.27.4696

21 June 2024

Identifiers

1 reference

11 November 2017

1 reference